How much revenue does Regenicin make?

Regenicin reported $0 in revenue for fiscal year 2022. In Q2 2023 revenue was $0.

What companies are similar to Regenicin?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Viropro Inc. (VPRO), Scopus BioPharma Inc. (SCPS), Arev Life Sciences Global Corp. (AREVF), Aeolus Pharmaceuticals, Inc. (AOLS).

Regenicin, Inc. (RGIN) Stock

About Regenicin, Inc.

Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of heal...

At a glance

Regenicin reported revenue of $0 for fiscal year 2022, and net income of -$692,216. In Q2 2023 (the quarter ended March 31, 2023) revenue was $0.

Figures from company filings; latest fiscal year ended September 30, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.